Raltitrexed and pemetrexed studies in mesothelioma have not shown improved quality of life nor prolonged survival compared with effective pleurodesis with thoracoscopic talc poudrage [3]

Journal of Clinical Oncology

Volumn 24, Issue 28, 2006, Pages 4667-

  Aelony, Yossef ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PEMETREXED; RALTITREXED; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; QUINAZOLINE DERIVATIVE; TALC; THIOPHENE DERIVATIVE;

ADJUVANT THERAPY; CANCER FATIGUE; CANCER PAIN; CANCER SURVIVAL; CATHETERIZATION; COST EFFECTIVENESS ANALYSIS; DYSPNEA; HUMAN; LETTER; LIFE EXPECTANCY; NAUSEA AND VOMITING; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURODESIS; PRIORITY JOURNAL; QUALITY OF LIFE; THORACOCENTESIS; THORACOSCOPY; CLINICAL TRIAL; MESOTHELIOMA; METHODOLOGY; NOTE; PLEURA TUMOR; TREATMENT OUTCOME;

CISPLATIN; CLINICAL TRIALS; GLUTAMATES; GUANINE; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; PLEURODESIS; QUALITY OF LIFE; QUINAZOLINES; TALC; THIOPHENES; TREATMENT OUTCOME;

EID: 33750590305     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.0267     Document Type: Letter

References (4)

1. Bottomley A, Gaafa R, Manegold C, et al: Short-term treatment-related symptoms and quality of life: Results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup study. J Clin Oncol 24:1435-1442, 2006
2. Aelony Y, Yao J: Prolonged survival after talc poudrage for malignant pleural mesothelioma: Case series. Respirology 10:649-655, 2005
3. Tremblay A, Michaud G: Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 129:362-368, 2006
4. Boyer MJ, Nassem J, Liepa AM, et al: Symptom and quality of life advantages for pemetrexed + cisplatin versus cisplatin in treatment of malignant pleural mesothelioma. Lung Cancer 41:S19, 2003 (suppl 2)